In 2018, the Medicines Patent Pool and Aurobindo signed a memorandum of understanding (MoU) agreeing to exchange information and business leads to fast-track the development and uptake of the antiretroviral dolutegravir (DTG). The MPP signed licences with ViiV Healthcare for DTG for adult and paediatric care and has signed sublicences with 13 generic manufacturers to produce DTG and DTG containing formulations for low- and middle-income countries. Aurobindo has a similar but direct licence for DTG with ViiV Healthcare. Under the terms of the new collaborative agreement, Aurobindo will share information on development timelines, regulatory status, technical challenges and sales of DTG in developing countries. The MPP may provide Aurobindo with technical assistance and inform procurers about the company’s state of readiness to supply DTG products. Aurobindo holds licences for other MPP-licensed treatments, lopinavir/ritonavir, atazanavir, daclatasvir, cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide.
The Medicines Patent Pool and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), an internationally-recognised leader in the fight against paediatric AIDS, signed a Memorandum of Understanding (MoU) in May 2018 to accelerate the uptake of new treatments in developing countries. The MPP and EGPAF will collaborate on improving access to more optimal and better-adapted paediatric ART formulations as well as multidrug-resistant tuberculosis treatments and, will explore additional therapeutic areas of mutual interest. The MoU calls for the exchange of information and other joint initiatives to speed national registration and adoption of important new products, notably in EGAPF’s partnering countries.
The MPP and ICAP at Columbia University signed a Memorandum of Understanding in May 2017 outlining a framework of collaboration to improve access to treatment for people living with HIV. The two organisations are working together to facilitate market introduction and uptake of jointly identified priority medicines for the prevention and treatment of HIV in low- and middle-income countries, particularly where ICAP operates. The MPP and ICAP have also agreed to explore opportunities for collaboration in tuberculosis, including TB/HIV co-infection. Founded in 2003 at Columbia University’s Mailman School of Public Health, ICAP is one of the largest U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) implementing partners. Both ICAP and the MPP are partners in the OPTIMIZE Consortium, led by Wits RHI and supported through the United States Agency for International Development (USAID). OPTIMIZE is a global partnership unifying distinct voices to achieve a common goal: accelerating access to simpler, safer and more affordable HIV treatment.
In September 2018, the Medicines Patent Pool (MPP) and the Medicines For All Institute (M4ALL) signed a Memorandum of Understanding (MOU) that will ultimately accelerate access to global health medicines in low- and middle-income countries (LMICs), by promoting the reduced cost of active pharmaceutical ingredients (APIs) – a major cost driver in treating infectious diseases in the developing world.
The MPP has several collaborative agreements with national and regional patent offices enabling regular updating of patent data for MedsPaL, its Medicines Patents and Licences Database.
The MPP collaborates with the following regional patent offices:
In addition, the MPP has agreements with the following patent offices, enabling regular updating of national patent status data:
The MPP and the National Medical Products Administration (NMPA), set up directly under the State Council of People’s Republic of China, signed a Memorandum of Understanding (MoU) in October 2018 to improve collaboration and exchange of information for MPP sublicensees based in China. The two parties are especially interested to ensure that MPP’s Chinese sublicensees are able to obtain Certificate of Pharmaceutical Products (COPPs) from NMPA for drugs for which these companies hold voluntary licences.
The MPP and Otsuka signed a Memorandum of Understanding (MoU) in October 2017 to make delamanid more available to children infected with multidrug-resistant tuberculosis. The MoU outlines areas of collaboration between the two parties including seeking funding to have a third-party develop the treatment and engaging in licensing activities to move this forward.
Leading product development partnership TB Alliance and the MPP signed a Memorandum of Understanding (MoU) in April 2016. The MoU outlines a multi-pronged collaboration to encourage the development of new tuberculosis (TB) regimens and to ensure their availability in low- and middle-income countries.
The MPP and TB Alliance signed a second Memorandum of Understanding (MOU) in October 2017 to facilitate third-party development of sutezolid-containing tuberculosis regimens. The MoU followed the sublicensing agreement signed by both organisations in March 2017 granting TB Alliance the rights to develop the treatment for drug-susceptible and drug-resistant TB patients.
In November 2017, the Medicines Patent Pool signed a Memorandum of Understanding (MoU) with the United States Agency for International Development (USAID) to accelerate the introduction of affordable new medicines for diseases that disproportionately affect developing countries. The MPP and USAID collaborate as part of the OPTIMIZE consortium, supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).
ViiV Healthcare and the MPP signed a Memorandum of Understanding in 2013, which sets out commitments between the MPP and ViiV Healthcare to collaborate in several areas, with the ultimate goal of making additional affordable quality medicines for children available. The MoU also contains a legally binding licence on paediatric abacavir (ABC) for use in the 118 countries where most children with HIV live.
En 2019, ViiV Healthcare, le Medicines Patent Pool (MPP) et Aurobindo ont signé un protocole d’accord relatif à l’échange d’informations et de pistes commerciales en vue d’accélérer le développement et la mise sur le marché du dolutégravir (DTG), un antirétroviral. Le MPP a signé des accords de licence avec ViiV Healthcare portant sur les versions adulte et pédiatrique du DTG, et des sous-licences avec 13 fabricants de médicaments génériques afin de produire du DTG et des formulations à base de DTG pour les pays à revenu faible et intermédiaire.
Aurobindo a signé un accord bilatéral sur le DTG avec ViiV Healthcare. En outre, depuis la signature du protocole d’accord avec le MPP en 2018, Aurobindo partage régulièrement avec celui-ci des données sur le développement et la commercialisation du DTG. Conformément à l’accord collaboratif signé par les trois parties en 2019, une partie des données d’Aurobindo sont communiquées à ViiV Healthcare par le MPP. Ces données sont précieuses pour ViiV Healthcare, car elles lui permettent d’évaluer l’impact global de l’ensemble des fabricants de génériques (bénéficiaires de licence du MPP et Aurobindo) sur l’accès au DTG.